A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Study to Evaluate the Safety and Immunogenicity of the Diphtheria, Tetanus and Three-components Acellular Pertussis Combined Vaccine, Adsorbed in Healthy Infants at the Age of 2 Months and 3 Months
Latest Information Update: 21 Jun 2023
At a glance
- Drugs Adsorbed diphtheria tetanus acellular pertussis combined vaccine-China National Biotec Group Company (Primary) ; Diphtheria tetanus and pertussis vaccine; Hib-DTaP-poliovirus vaccine
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors China National Biotec Group
- 15 Jun 2023 Planned primary completion date changed from 22 Apr 2023 to 22 Sep 2023.
- 15 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 29 Oct 2021 New trial record